



Universiteit
Leiden
The Netherlands

The association between sarcopenia and adverse outcomes after complex endovascular aortic repair

Warmerdam, B.W.; Rijswijk, C.S. van; Droop, A.; Lucassen, C.J.; Hamming, J.F.; Schaik, J. van; Vorst, J.R. van der

Citation

Warmerdam, B. W., Rijswijk, C. S. van, Droop, A., Lucassen, C. J., Hamming, J. F., Schaik, J. van, & Vorst, J. R. van der. (2024). The association between sarcopenia and adverse outcomes after complex endovascular aortic repair. *The Journal Of Cardiovascular Surgery*, 65(3), 256-264. doi:10.23736/S0021-9509.23.12821-7

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/4302734>

Note: To cite this publication please use the final published version (if applicable).

ORIGINAL ARTICLE
VASCULAR SECTION

The association between sarcopenia and adverse outcomes after complex endovascular aortic repair

Britt W. WARMERDAM¹, Carla S. van RIJSWIJK², Anneke DROOP³, Claudia J. LUCASSEN³,
Jaap F. HAMMING¹, Jan van SCHAIK¹, Joost R. van der VORST¹ *¹Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands; ²Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands; ³Department of Dietetics, Leiden University Medical Center, Leiden, the Netherlands*Corresponding author: Joost R. van der Vorst, Albinusdreef 2, 2300 RC Leiden, the Netherlands. E-mail: j.r.van_der_vorst@lumc.nl

A B S T R A C T

BACKGROUND: Sarcopenia is identified as a predictive factor for adverse outcomes after complex endovascular aortic repair (complex EVAR). Consensus on preferred parameters for sarcopenia is not yet reached. The current study compares three CT-assessed parameters on their association with adverse outcomes after complex EVAR.**METHODS:** This was a single-center retrospective cohort study. Psoas Muscle Index (PMI), Skeletal Muscle Index (SMI), and lean psoas muscle area (LPMA) were examined by CT-segmentation. PMI, SMI, and LPMA were analyzed as continuous variables. In addition, cut-off values from previous research were used to diagnose patients as sarcopenic or non-sarcopenic. Outcomes were: all-cause mortality, major adverse events (MAE), length of hospital stay, and non-home discharge. A sub-analysis was made for severe sarcopenia; sarcopenia combined with low physical performance (gait speed, Time Up and Go test, Metabolic Equivalent of Task-score).**RESULTS:** We included 101 patients. A higher PMI (HR=0.590, CI: 0.374-0.930, P=0.023), SMI (HR=0.453, CI: 0.267-0.768, P=0.003), and LPMA (HR=0.559, CI: 0.333-0.944, P=0.029) were associated with a lower risk of mortality. Sarcopenia based on cut-off values for PMI and LPMA was not significantly associated with survival. Sarcopenia based on SMI did present a higher mortality risk (P=0.017). A sub-analysis showed that severely sarcopenic patients were at even higher risk of mortality (P=0.036). None of the parameters were significantly associated with the other outcomes.**CONCLUSIONS:** SMI had a slightly stronger association with mortality compared to PMI and LPMA. High-risk patients were selected by adding physical performance scores. Future research could focus on complex EVAR-specific PMI and LPMA cut-off values.(Cite this article as: Warmerdam BW, van Rijswijk CS, Droop A, Lucassen CJ, Hamming JF, van Schaijk J, *et al.* The association between sarcopenia and adverse outcomes after complex endovascular aortic repair. J Cardiovasc Surg 2023 Nov 21. DOI: 10.23736/S0021-9509.23.12821-7)**KEY WORDS:** Abdominal aortic aneurysm; Endovascular aneurysm repair; Sarcopenia; Preoperative exercise.

Complex endovascular aortic repair (complex EVAR), including fenestrated EVAR (FEVAR) and branched EVAR (BEVAR), provides a less invasive treatment option compared to open repair for patients with juxtarenal and suprarenal aortic aneurysms.^{1,2} Although complex EVAR provides better early post-operative outcomes compared to open repair, it is an extensive surgical procedure with considerable morbidity and mortality.³⁻⁵ This necessitates evidence-based patient risk assessment and selection. A systematic review on risk factors for mortality after aortic aneurysm repair, including FEVAR, defined oxygen-dependent chronic obstructive pulmonary disease (COPD)

and dialysis as the greatest risk factors. In addition, female gender, diabetes, age, and ASA-score were negatively associated with survival.⁶

In other surgical fields, especially oncologic surgery, sarcopenia has been established as a predictive factor for adverse outcomes.^{7,8} According to the European Working Group on Sarcopenia in Older People (EWG-SOP), sarcopenia is defined as a progressive skeletal muscle disease. It is of multifactorial cause; age, malnutrition, physical inactivity, and systemic disease can play a role, among other factors. Sarcopenia is suspected when a patient has low muscle strength, and is confirmed by low muscle quan-

tity or quality. It is considered severe if combined with low physical performance.^{9, 10} For muscle quantity, CT-assessed muscle area is an often-used parameter.^{11, 12} However, definitive consensus on the preferred method and cut-off points is not yet reached.¹³

Recently, studies have focused on sarcopenia in complex EVAR patients and have shown that sarcopenia based on CT-assessed low psoas muscle mass is a predictor for adverse outcomes.¹⁴⁻¹⁷ Due to time-effectiveness, psoas muscle area is often used to identify muscle quantity. However, measuring whole skeletal muscle area (SMA) at the level of lumbar 3 has been proposed as a more accurate method.¹⁸⁻²⁰ The current study reports on sarcopenia in complex EVAR patients by using three parameters based on CT-assessed psoas muscle, as well as total skeletal muscle. Our aim is to compare the different parameters on their association with adverse outcomes, and to identify whether CT-assessed sarcopenia combined with physical performance scores can assess the highest-risk complex EVAR patients. Not only could it serve as a tool for patient selection, it could also provide a target for prehabilitation, as sarcopenia is partially modifiable.²¹

Materials and methods

Patient inclusion and data collection

All patients that underwent complex EVAR between July 2013 and June 2022 in the Leiden University Medical Center (LUMC) were consecutively included based on their date of surgery. Complex EVAR included FEVAR, BEVAR, and branched or fenestrated arch-EVAR. A decision to treat is usually made when the aneurysm reaches a diameter of 6 cm. Data on patient characteristics and complications during follow-up were subtracted from patients' medical records and entered into a computerized secured database. A certificate of no objection was issued by the LUMC Medical Ethics Committee (METC), as is required in our institution (registration number: 2022-034, July 5th, 2022). Due to the merely retrospective character of our study and the fact that there was no interference in the standard care pathway, explicit patient consent was not obtained.

Identifying sarcopenia

All patients routinely underwent a preoperative CT-scan. A cross-sectional slice of 5 mm thickness at the level of L3 was identified and examined in the arterial contrast-phase. A slice was selected on which the lateral tips of both transverse processes were visible. If multiple slices at L3 met this




Figure 1.—Example of a segmented scan at L3 for total skeletal muscle area.

criterion, the most cranial one was used. Slices were analyzed using SliceOmatic (Tomovision, Montreal, Canada); a software tool, clinically available and widely used for this purpose.^{22, 23} Muscle (including m. rectus abdominis, m. obliquus internus and externus, m. transversus, m. psoas major and minor, m. erector spinae, and m. quadratus lumborum) was identified by using a Hounsfield unit threshold of -29 to +150 (Figure 1).²⁴⁻²⁶ Based on visual evaluation of the segmented contours, adjustments were made if necessary. For each scan, segmentation time was registered (seconds).

Because muscle area is related to total body muscle mass, SMA and PMA were corrected for height into the Skeletal Muscle Index (SMI) and Psoas Muscle Index (PMI, cm²/m²). LPMA (cm²×HU) was calculated as [(PMA right + PMA left) / 2] × mean psoas muscle density (HU). Definitive consensus on cut-off values for sarcopenia is not yet reached. In order to place our results in existing literature, the values used in this paper are based on previous research. SMI values were 52.4 cm²/m² for men and 38.5cm²/m² for women.²⁴ For PMI, these values were 5.40 cm²/m² and 3.56 cm²/m² for men and women respectively.²⁷ For LPMA, sarcopenia was considered present if LPMA was <350 cm²×HU.¹⁵

Outcomes of interest

Baseline patient characteristics were: demographics, comorbidities, American Society of Anesthesiologists (ASA)-score, Body Mass Index (BMI, kg/m²), procedure

complexity, PMI, SMI, and LPMA. It was assessed whether the presence of sarcopenia based on PMI, SMI, and LPMA was associated with adverse outcomes. These parameters were also analyzed as continuous variables. The primary outcome was all-cause mortality. Secondary outcomes were: increased length of hospital stay, discharge to a rehabilitation center, and major adverse events (MAE). MAE were defined as complications with a Clavien-Dindo score of ≥ 3 . This included all complications needing a (minor or major) radiological, surgical, or laparoscopic intervention, as well as organ failure leading to ICU admission (including spinal ischemia), and death.²⁸

As of 2017, complex EVAR patients were routinely referred for preoperative geriatric, physiotherapeutic, and dietetic screening. Time Up-and-Go test (TUG), and gait speed were performed. Metabolic Equivalent of Task-score was assessed during preoperative anesthetic screening.²⁹ A sub-analysis for the primary outcome and MAE was made for severely sarcopenic patients. This was considered to be the case if a sarcopenic patient (based on either PMI, SMI, or LPMA) had a low physical performance based on low MET-score (1-4), slow gait speed (≤ 0.8 m/s), and/or high TUG-score (≥ 20 s).^{10, 29, 30}

Statistical analysis

To compare baseline characteristic, patients were divided into six groups: patients with and without sarcopenia based on PMI (group 1a and 1b), patients with and without sarcopenia based on SMI (group 2a and 2b), and patients with and without sarcopenia based on LPMA (group 3a and 3b). Categorical patient characteristics were expressed by number of patients and percentages. Continuous variables were tested for normal distribution using histograms, Q-Q plots, and the Shapiro-Wilk Test. Normally distributed data was expressed as mean with the standard deviation. Median with the interquartile range (Q1-Q3) was used in case of skewed distribution. Groups 1a *versus* 1b, 2a *versus* 2b, and 3a *versus* 3b were compared on baseline characteristics using the independent *t*-test for continuous normally distributed data, Chi-square Test for categorical data, and the Mann-Whitney U Test for skewed data. When less than five events occurred, the Fisher's Exact Test was used instead of Chi-square.

All-cause mortality in group 1a *versus* group 1b, group 2a *versus* 2b, and group 3a *versus* 3b was tested by Kaplan-Meier with log-rank testing. Cox regression was used for a multivariate analysis of survival, corrected for variables that were associated with survival in univariate analysis. The association of PMI, SMI, and LPMA with adverse out-

comes was also tested with these parameters as continuous variables. PMI, SMI, and LPMA were adjusted by dividing them by their standard deviations, in order to compare hazard ratios. To compare secondary outcomes in the different groups, the same tests were used as for the baseline characteristic analyses. With PMI, SMI, and LPMA as continuous outcomes, logistic regression analysis was used to assess the categorical secondary outcomes, and linear regression analysis for continuous secondary outcomes. All analyses were made using IBM SPSS Statistics v. 27.

Results

Selection of CT-scans

Figure 2 shows a flow-chart of patient inclusion. Between 2013 and June 2022, 104 patients underwent complex EVAR in the Leiden University Medical Center (LUMC). In three patients, the preoperative CT-scan was not suitable for muscle segmentation, either because it was not scanned until the level of L3 (N=2), or because the correct level could not be determined due to extreme scoliosis (N=1). This left 101 patients to be included in the analysis. In seven patients, the scan was suitable for segmentation of the psoas muscles but not for whole skeletal muscle. This was either due to anatomic aberrations, or due to the scan being cut off on both sides, impeding segmentation of the abdominal wall muscles. In four patients the arterial phase was not suitable for segmentation, and the non-contrast scan was used. Median time between the scan and surgery was 140.0 days (IQR: 110.0-175.8).

Patient characteristics

Eighty-four of 101 patients (83%) were male, and mean age was 73.8 ± 6.1 years. Based on PMI cut-off values,




Figure 2.—Flow-chart of patient inclusion.

24 patients (24%) were sarcopenic. Using LPMA, 53% was considered sarcopenic. Of the 94 patients included in skeletal muscle segmentation, 64 (68%) were considered sarcopenic. Median segmentation time was 41.1 seconds (IQR: 34.6-51.6) for the psoas muscles and 163.1 seconds (IQR: 133.9-193.7) for total skeletal muscle.

A comparison of sarcopenic versus non-sarcopenic patients (Supplementary Digital Material 1: Supplementary Table I) based on PMI showed that a higher number of patients in the sarcopenic group had undergone previous AAA repair (38% vs. 13%, $P=0.014$). A comparison of the groups based on LPMA showed that there were significantly more women in the sarcopenic group (17 [40%] vs. 0, $P<0.001$) and more patients with cardiovascular comorbidities other than AF or MI/ACS (22 [42%] vs. 10 [21%], $P=0.033$). The same analysis based on SMI showed that sarcopenic patients in this subgroup had a significantly lower mean BMI (25.5 ± 3.5 vs. 28.3 ± 3.6 , $P<0.001$).

Association between sarcopenia and mortality

Median follow-up time was 26.0 months (IQR: 4.0-47.9). All-cause mortality during follow-up was 28% ($N=28$). Based on PMI, estimated mean survival in months was 38.3 (95% CI: 27.2-49.4) and 65.9 (95% CI: 57.0-74.9) for sarcopenic and non-sarcopenic patients respectively ($P=0.049$). Using LPMA cut-off values, mean survival was 45.3 (95% CI: 33.0-57.6) in the sarcopenic group, and 71.1 (95% CI: 62.3-79.9) in the non-sarcopenic group ($P<0.001$). Based on SMI, estimated mean survival was 52.1 (95% CI: 43.2-61.0) and 74.6 (95% CI: 62.0-87.1)

TABLE I.—Univariable analyses for all-cause mortality.

Variable	HR	95% CI	Coefficient	P value
Gender (male)	0.318	0.144-0.705	-1.145	0.005*
Age	0.974	0.917-1.035	-0.026	0.392
BMI	0.936	0.831-1.055	0.066	0.280
ASA of ≥ 3	2.524	1.063-5.995	0.926	0.036*
Hypertension	1.367	0.553-3.377	0.313	0.498
Smoking				
Past	0.983	0.388-2.494	-0.017	0.972
Active	0.859	0.311-2.374	-0.152	0.770
Diabetes	1.021	0.627-1.662	0.021	0.933
Hypercholesterolemia	0.625	0.275-1.423	-0.470	0.263
MI/ACS	0.506	0.215-1.191	-0.682	0.119
AF	2.469	1.039-5.864	0.904	0.041*
Other cardiovascular disease	4.625	2.135-10.020	1.532	<0.001*
Stroke	0.687	0.276-1.708	-0.376	0.419
COPD	1.572	0.690-3.582	0.453	0.281
PVD	1.237	0.500-3.061	0.212	0.646
Previous AAA repair	2.757	1.237-6.142	1.014	0.013*
Malignancy				
Past	1.067	0.430-2.651	0.065	0.889
Active	0.738	0.099-5.510	-0.304	0.738
Procedure complexity**				
Grade 2	1.241	0.332-4.780	0.216	0.754
Grade 3	2.039	0.527-7.270	0.712	0.272
Grade 4	4.389	1.032-18.670	1.479	0.044*
PMI	0.573	0.435-0.755	-0.556	<0.001*
SMI	0.913	0.868-0.961	-0.091	<0.001*
LPMA	0.993	0.990-0.996	-0.007	<0.001*

BMI: Body Mass Index (kg/m^2); ASA: American Association of Anesthesiologists; MI/ACS: myocardial infarction/acute coronary syndrome; AF: atrial fibrillation; COPD: chronic obstructive pulmonary disease; PVD: peripheral vascular disease; AAA: abdominal aortic aneurysm; PMI: psoas muscle index; SMI: skeletal muscle index; LPMA: lean psoas muscle area.

*Statistically significant association, based on a P value cut-off of <0.05 ;

**procedure complexity: Grade 2: 3 or 4 fenestrated EVAR. Grade 3: branched-EVAR. Grade 4: branched-fenestrated EVAR combinations, arch EVAR, and emergency cases.




Figure 3.—Kaplan-Meier curves for PMI (38.3, 95% CI: 27.2-49.4 vs. 65.9, 95% CI: 57.0-74.9, $P=0.049$), for LPMA (45.3, 95% CI: 33.0-57.6 vs. 71.1, 95% CI: 62.3-79.9, $P<0.001$), and SMI (52.1, 95% CI: 43.2-61.0 vs. 74.6, 95% CI: 62.0-87.1, $P=0.064$), for sarcopenic and non-sarcopenic patients respectively.

for sarcopenic and non-sarcopenic patients respectively ($P=0.064$). Figure 3 depicts the survival curves.

Table I shows that female gender, AF, other cardiovascular disease, $ASA \geq 3$, higher procedure complexity, and previous AAA repair were associated with a higher chance of mortality. A multivariate analysis for sarcopenia based on PMI cut-off values (HR: 1.574, 95% CI: 0.591-4.190, $P=0.364$) no longer showed a statistically significant association with mortality. The same accounted for LPMA (HR: 2.534, 95% CI: 0.940-6.829, $P=0.066$), whereas the association between sarcopenia based on SMI became statistically significant after adjustment (HR: 3.624, 95% CI: 1.263-10.398, $P=0.017$).

PMI, SMI, and LPMA were also analyzed as continuous variables. They were adjusted by dividing them by their standard deviations (1.5, 7.7, and 146.5, respectively), in order to be able to compare hazard ratios (HR). Univariate analysis showed that a higher PMI (HR: 0.434 per 1 standard deviation, 95% CI: 0.287-0.656, $P<0.001$), SMI (HR: 0.496, 95% CI: 0.334-0.736, $P<0.001$), and LPMA (HR: 0.361, 95% CI: 0.222-0.589, $P<0.001$) were associated with a lower mortality risk. In a multivariate cox regression analysis, the statistically significant negative association remained present for PMI (HR: 0.590, 95% CI: 0.374-0.930, $P=0.023$), SMI (HR: 0.453, 95% CI: 0.267-0.768, $P=0.003$), and LPMA (HR: 0.559, 95% CI: 0.333-0.944, $P=0.029$). Table II shows an overview of these results. No multicollinearity was shown between SMI, PMI, and LPMA and the factors in de multivariate analyses, as well as possible other factors causing collinearity in our dataset

TABLE II.—Multivariate analysis of all-cause mortality adjusted for gender, ASA-score, AF, other cardiovascular disease, previous AAA repair, and procedure complexity.

Variable	HR	95% CI	Coefficient	P value
Unadjusted PMI	0.704	0.520-0.953	-0.351	0.023**
Unadjusted SMI	0.902	0.843-0.966	-0.103	0.003**
Unadjusted LPMA	0.996	0.992-1.000	-0.004	0.029**
Adjusted* PMI	0.590	0.374-0.930	-0.528	0.023**
Adjusted* SMI	0.453	0.267-0.768	-0.528	0.003**
Adjusted* LPMA	0.559	0.333-0.944	-0.581	0.029**
Sarcopenia based on PMI cut-off	1.574	0.591-4.190	0.453	0.364
Sarcopenia based on SMI cut-off	3.624	1.263-10.398	1.288	0.017**
Sarcopenia based on LPMA cut-off	2.534	0.940-6.829	0.930	0.066

ASA: American Association of Anesthesiologists; AF: atrial fibrillation; AAA: abdominal aortic aneurysm; PMI: Psoas Muscle Index; SMI: Skeletal Muscle Index; LPMA: lean psoas muscle area.

*PMI, SMI, and LPMA were divided by their standard deviation in order to enable interpretation of hazard ratios; **statistically significant association based on a P value cut-off of <0.05 .

(COPD, BMI, diabetes mellitus); all variance inflation factors were below 2, and tolerance was above 0.1.

Association between sarcopenia and secondary adverse outcomes

The secondary outcomes were MAE (a composite end-point of complications with a Clavien-Dindo score of ≥ 3 , including death by surgical complications), non-home discharge, and length of hospital stay. These outcomes were compared between patients with and without sarcopenia based on SMI, PMI, and LPMA. In addition, these parameters were analyzed as continuous variables (Table III, IV). None of the outcomes were statistically significant, which is presented in further detail below.

In the total patient group, 32 patients (32%) suffered a MAE, of whom seven died (7%). There was no statistical difference in the number of patients with a MAE when comparing patients with and without sarcopenia based on PMI (8 [33%] vs. 24 [31%], $P=1.000$), based on SMI (19 [30%] vs. 12 [40%], $P=0.353$), and based on LPMA (20

TABLE III.—Comparison of secondary outcomes between patients with and without sarcopenia based on SMI, PMI, and LPMA.

Outcome	Variable	OR	95% CI	P-value
MAE	SMI	0.970	0.917-1.027	0.296
	PMI	0.960	0.724-1.272	0.774
	LPMA	0.998	0.995-1.002	0.329
Non-home discharge	SMI	0.931	0.867-0.999	0.048*
	SMI corrected	0.964	0.890-1.044	0.370
	PMI	0.763	0.535-1.087	0.134
	LPMA	0.996	0.992-1.000	0.072
Length of stay	SMI	-0.135	-0.372-0.102	0.261
	PMI	-0.004	-1.159-1.151	0.994
	LPMA	-0.001	-0.130-0.110	0.873

MAE: major adverse events; SMI: Skeletal Muscle Index; PMI: Psoas Muscle Index; LPMA: lean psoas muscle area.

*Statistically significant association based on a P value cut-off of <0.05 .

TABLE IV.—Odds ratios of SMI, PMI, and LPMA as continuous variables for the secondary outcomes.

Outcome	Variable	Sarcopenia		P value
		Yes	No	
MAE	SMI	19 (30%)	12 (40%)	0.353
	PMI	8 (33%)	24 (31%)	1.000
	LPMA	20 (38%)	12 (25%)	0.202
Non-home discharge	SMI	14 (23%)	4 (15%)	0.568
	PMI	5 (23%)	14 (19%)	0.765
	LPMA	12 (26%)	7 (15%)	0.304
Length of stay (median, IQR)	SMI	6.0 (5.0-12.8)	7.0 (4.0-12.0)	0.828
	PMI	5.0 (3.0-10.0)	6.5 (5.0-12.0)	0.300
	LPMA	6.0 (5.0-13.0)	6.0 (3.0-09.0)	0.172

MAE: major adverse events; SMI: Skeletal Muscle Index; PMI: Psoas Muscle Index; LPMA: lean psoas muscle area; IQR: interquartile range.

[38%] vs. 12 [25%], $P=0.202$). Logistic regression also showed no statistically significant association between the different parameters and MAE (Table III, IV).

For PMI, five patients (23%) in the sarcopenic group and 14 patient (19%) in the non-sarcopenic group were discharged to a rehabilitation center or nursing home ($P=0.765$). For SMI, this was 14 (23%) versus 4 (15%) for sarcopenic and non-sarcopenic patients respectively ($P=0.568$), and for LPMA 12 (26%) sarcopenic versus 7 (15%) non-sarcopenic patients ($P=0.304$). Logistic regression also showed no significant association for PMI and LPMA (Table III, IV). However, logistic regression did show a negative association between SMI and non-home discharge. Corrected for male gender (OR: 0.233, 95% CI: 0.068-0.800, $P=0.021$) and COPD (OR: 3.000, 95% CI: 1.033-8.708, $P=0.043$), which were identified as being associated with non-home discharge, this was no longer significant (Table III).

A comparison of the length of hospital stay showed no statistically significant differences between sarcopenic and non-sarcopenic patients, based on PMI (median: 5.0, IQR: 3.0-10.0 vs. median: 6.5, IQR: 5.0-12.0, $P=0.300$), LPMA (median 6.0, IQR: 5.0-13.0 vs. median: 6.0, IQR: 3.0-9.0, $P=0.172$), and SMI (median: 6.0, IQR: 5.0-12.8 vs. median: 7.0, IQR: 4.0-12.0, $P=0.828$). A linear regression analysis also showed no statistically significant association for these parameters as continuous variables (Table III).

Association of severe sarcopenia with mortality and MAE

Physical performance based on gait speed, TUG-score, and/or MET-score was assessed in 90 of 101 patients (89%). In this subgroup, 17 patients were considered severely sarcopenic (17%), 55 patients (55%) were sarcopenic but not severe, and 18 patients (18%) did not have sarcopenia based on either PMI, SMI, or LPMA. There were two patients with a low physical performance score, without having sarcopenia. Kaplan Meier survival analysis (Figure 4) showed a statistically significant difference in mortality risk between severely sarcopenic (33.6 months, 95% CI: 21.1-46.1) and sarcopenic patients (63.9 months, 95% CI: 52.6-75.3, $P=0.012$), and between severely sarcopenic and non-sarcopenic patients (80.0 months, 95% CI: 70.3-89.8, $P<0.001$). A multivariate cox-regression analysis, adjusted for the previously identified confounders also showed a statistically significant association between severe sarcopenia and mortality (HR: 10.525 95% CI: 1.163-95.239, coefficient 2.354, $P=0.036$), compared to non-sarcopenic patients in this




Figure 4.—Kaplan-Meier curves for severely sarcopenic patients (33.6 months, 95% CI: 21.1-46.1), compared to non-sarcopenic (80.0 months, 95% CI: 70.3-89.8, $P<0.001$), and sarcopenic patients (63.9 months, 95% CI: 52.6-75.3, $P=0.012$), in the sub-group analysis.

subgroup. There was no significant difference in the number of MAE's in severely sarcopenic (N.=8, 47%), sarcopenic (N.=17, 31%), and non-sarcopenic patients (N.=4, 22%, $P=0.286$).

Discussion

Association of PMI, SMI, and LPMA with adverse outcomes

After adjustment for confounding factors, a lower PMI, SMI, and LPMA were all associated with a higher risk of mortality, with a slightly stronger association for SMI. Sarcopenia based on cut-off values for PMI and LPMA was not significantly associated with survival, whereas sarcopenia based on SMI did lead to a significantly higher mortality risk. A sub-analysis based on physical performance parameters showed that severely sarcopenic patients were at even higher risk of mortality. None of the parameters were significantly associated with secondary adverse outcomes. The fact that psoas muscle measuring takes less time, in addition to more scans being appropriate for psoas segmentation, would favor PMI and LPMA above SMI in clinical application.

The discrepancy between the significant association of PMI and LPMA with mortality as continuous variables

and the non-association of these variables based on cut-off values could indicate that the cut-off values did not fit our population. Cut-off points depend on various characteristics, such as age and height, and therefore vary between different countries and patient cohorts. The number of patients in our cohort impedes the identification of robust cut-off points. A recent study by Bradley *et al.* defined cut-off points for SMI and PMI in a cohort of patients undergoing EVAR (N.=674), including fenestrated- and branched-EVAR (N.=133).³¹ When comparing their cut-off points with the values used in our study, Bradley *et al.* defines slightly lower cut-off values for SMI and slightly higher for PMI. This could indicate an underestimation of the number of sarcopenic patient in our cohort based on PMI and an overestimation based on SMI, although these cut-off points were identified for conventional and complex EVAR patients combined. Future studies on complex EVAR patients could focus on validating these cut-off points by Bradley *et al.*, in order for these parameters to be applied in clinical practice.

Results in context

Previous research based on PMA by Alenezi *et al.* reported an increased all-cause mortality risk for lower PMA. Although a different parameter was used, this is in accordance with our findings that a higher psoas muscle quantity, whether it be adjusted for height into PMI or for density into LPMA, is associated with a lower mortality risk.¹⁶ Kärkkäinen *et al.* reported a comparable hazard ratio for LPMA and all-cause mortality (0.59, 95% CI: 0.40-0.87, P=0.008), compared to our hazard ratio (0.56, 95% CI: 0.33-0.94, P=0.029).¹⁵ Using their LPMA cut-off values, we were able to detect a difference in all-cause mortality between sarcopenic and non-sarcopenic patients. However, after adjustment for confounders this was no longer significant (P=0.066).

Alenezi *et al.* (PMA) and Kärkkäinen *et al.* (LPMA) found that their parameters were predictive for MAE, while this was not supported by our results, even when analyzing severely sarcopenic patients. Although these discrepancies might be due to the fact that both studies included substantially larger patient cohorts of 257 and 504 patients respectively, it is an interesting finding which might indicate that in our cohort sarcopenic patients were fit enough to undergo surgery, but were more likely to die of other causes on a longer-term compared to non-sarcopenic patients.^{14, 16}

The EWGSOP-criteria propose that physical performance status can be used to identify severely sarcopenic

patients at an even higher risk for adverse outcomes.¹⁰ This was supported by our results, by using TUG, gait speed, and MET-score as indicators of physical performance. In Kärkkäinen *et al.*, ASA-score was used for risk stratification of extremely high-risk patients. Future research could focus on identifying preferred physical performance parameters.

Clinical application

The decision if and when an aneurysm should be treated, is mainly based on weighing the risk of rupture against the short-term and long-term risks of surgery.^{32, 33} Being at higher risk of mortality due to individual characteristics could be taken into this equation. Sarcopenia combined with physical performance parameters is proposed as such a characteristic, although regarding short term mortality due to surgery-related complications this is not supported by our results.

As opposed to other risk factors for adverse outcomes, such as COPD and age, sarcopenia is partially modifiable. Malnutrition and physical inactivity, two contributors to sarcopenia, have been targeted for optimization in prehabilitation programs.²¹ Given the fact that complex EVAR is generally elective surgery, time during surveillance or time between the decision to treat and the actual procedure could be used to optimize patients. A meta-analysis on prehabilitation programs for patients undergoing major abdominal surgery concluded that pulmonary morbidity can be reduced by prehabilitation.³⁴ Another review on prehabilitation prior to intra-abdominal surgery stated that pulmonary and all-cause complications can be reduced by prehabilitation, but was inconclusive on the ability to decrease mortality.³⁵ A review on prehabilitation in open and endovascular aortic repair concluded that exercise therapy might reduce cardiac and renal complications.³⁶

However, all reviews stated that more research is necessary to validate these findings. Furthermore, these studies investigated whether prehabilitation improved physical function, and did not comment on post-prehabilitation changes in sarcopenia. A randomized controlled trial showed a significant increase in SMI in community-dwelling healthy elderly, who underwent a resistance-exercise intervention program.³⁷ A study among elderly nursing-home residents reported a decrease in the prevalence of sarcopenia after three months of resistance-exercise training, but found no significant decrease in SMI.³⁸ To our knowledge, the safety of such programs and their effect on muscle mass has not yet been studied among complex aneurysm patients.

Limitations of the study

This study presented a real-world complex EVAR patient group in a non-high-volume university hospital. Consequently, the sample size was relatively small. This limits the analyses that can be performed, and could confine the external validity. However, a comparison with larger sized studies showed comparable results for the main outcome.

Several baseline characteristics were analyzed as possible confounders or factors of multicollinearity. For example, physical inactivity can cause sarcopenia, which is likely to be present in patients suffering from COPD. COPD could therefore correlate with sarcopenia in a predictive model for mortality. In our data however, no significant collinearity was shown and we adjusted for confounding factors in our multivariate analyses. It is however possible that we did not examine all relevant variables. Due to the restricted sample size, the number of variables in multivariate analysis is limited. As mentioned in the introduction, sarcopenia is a disease of multifactorial cause. It could also be argued whether, in a way, sarcopenia is already partially adjusted for these confounding factors, and whether including these confounding factors in multivariate analyses will have the desired effect.

Conclusions

As continuous variables, PMI, SMI, and LPMA were all associated with mortality, with SMI as a slightly stronger predictor. When using cut-off values for PMI, SMI, and LPMA, only sarcopenia based on SMI was associated with mortality after adjustment for confounders. In our cohort, none of the factors were associated with MAE, including surgery-related death. Psoas segmentation took less time, was possible in a higher number of scans, and therefore has practical advantages compared to total skeletal muscle segmentation. Future research, preferably with a higher number of patients, could be conducted to determine optimal PMI and LPMA cut-off values for complex EVAR patients. Furthermore, the highest-risk patients were identified by adding physical parameters. Selecting high risk patients can aid in clinical decision making and identifies a group that might benefit from prehabilitation strategies.

References

1. Kansagra K, Kang J, Taon MC, Ganguli S, Gandhi R, Vatakencherry G, *et al.* Advanced endografting techniques: snorkels, chimneys, periscopes, fenestrations, and branched endografts. *Cardiovasc Diagn Ther* 2018;8(Suppl 1):S175–83.

2. Malina M, Resch T, Sonesson B. EVAR and complex anatomy: an update on fenestrated and branched stent grafts. *Scand J Surg* 2008;97:195–204.
3. Varkevisser RR, O'Donnell TF, Swerdlow NJ, Liang P, Li C, Uteet KH, *et al.* Fenestrated endovascular aneurysm repair is associated with lower perioperative morbidity and mortality compared with open repair for complex abdominal aortic aneurysms. *J Vasc Surg* 2019;69:1670–8.
4. Manunga J, Sullivan T, Garberich R, Alden P, Alexander J, Skeik N, *et al.* Single-center experience with complex abdominal aortic aneurysms treated by open or endovascular repair using fenestrated/branched endografts. *J Vasc Surg* 2018;68:337–47.
5. Uteet KH, Zettervall SL, Soden PA, Darling J, Verhagen HJ, Schermerhorn ML. Perioperative outcome of endovascular repair for complex abdominal aortic aneurysms. *J Vasc Surg* 2017;65:1567–75.
6. Khashram M, Williman JA, Hider PN, Jones GT, Roake JA. Systematic Review and Meta-analysis of Factors Influencing Survival Following Abdominal Aortic Aneurysm Repair. *Eur J Vasc Endovasc Surg* 2016;51:203–15.
7. Jones K, Gordon-Weeks A, Coleman C, Silva M. Radiologically Determined Sarcopenia Predicts Morbidity and Mortality Following Abdominal Surgery: A Systematic Review and Meta-Analysis. *World J Surg* 2017;41:2266–79.
8. Malietzis G, Aziz O, Bagnall NM, Johns N, Fearon KC, Jenkins JT. The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: a systematic review. *Eur J Surg Oncol* 2015;41:186–96.
9. Cruz-Jentoft AJ, Sayer AA. Sarcopenia [published correction appears in *Lancet*. 2019 Jun 29;393(10191):2590]. *Lancet* 2019;393:2636–46.
10. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, *et al.* Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis [published correction appears in *Age Ageing*. 2019 Jul 1;48(4):601]. *Age Ageing* 2019;48:16–31.
11. Tolonen A, Pakarinen T, Sassi A, Kyttä J, Cancino W, Rinta-Kiikka I, *et al.* Methodology, clinical applications, and future directions of body composition analysis using computed tomography (CT) images: A review. *Eur J Radiol* 2021;145:109943.
12. Amini B, Boyle SP, Boutin RD, Lenchik L. Approaches to Assessment of Muscle Mass and Myosteatosis on Computed Tomography: A Systematic Review. *J Gerontol A Biol Sci Med Sci* 2019;74:1671–8.
13. Albano D, Messina C, Vitale J, Sconfienza LM. Imaging of sarcopenia: old evidence and new insights. *Eur Radiol* 2020;30:2199–208.
14. Kärkkäinen JM, Oderich GS, Tenorio ER, Pather K, Oksala N, Macedo TA, *et al.* Psoas muscle area and attenuation are highly predictive of complications and mortality after complex endovascular aortic repair. *J Vasc Surg* 2021;73:1178–1188.e1.
15. Kärkkäinen JM, Tenorio ER, Oksala N, Macedo TA, Sen I, Mendes BC, *et al.* Pre-operative Psoas Muscle Size Combined With Radiodensity Predicts Mid-Term Survival and Quality of Life After Fenestrated-Branched Endovascular Aortic Repair. *Eur J Vasc Endovasc Surg* 2020;59:31–9.
16. Alenezi AO, Tai E, Jaber A, Brown A, Mafeld S, Roche-Nagle G. Adverse Outcomes after Advanced EVAR in Patients with Sarcopenia. *Cardiovasc Intervent Radiol* 2021;44:376–83.
17. Mezzetto L, D'Oria M, Mani K, Scali S, Bastos Gonçalves F, Trimarchi S, *et al.* Scoping review of radiologic assessment and prognostic impact of skeletal muscle sarcopenia in patients undergoing endovascular repair for aortic disease. *J Vasc Surg* 2022;76:1407–16.
18. Rollins KE, Gopinath A, Awwad A, Macdonald IA, Lobo DN. Computed tomography-based psoas skeletal muscle area and radiodensity are poor sentinels for whole L3 skeletal muscle values. *Clin Nutr* 2020;39:2227–32.
19. Baracos VE. Psoas as a sentinel muscle for sarcopenia: a flawed premise. *J Cachexia Sarcopenia Muscle* 2017;8:527–8.

20. Rutten IJ, Ubachs J, Kruitwagen RF, Beets-Tan RG, Olde Damink SW, Van Gorp T. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. *J Cachexia Sarcopenia Muscle* 2017;8:630–8.
21. Whittle J, Wischmeyer PE, Grocott MP, Miller TE. Surgical Prehabilitation: nutrition and Exercise. *Anesthesiol Clin* 2018;36:567–80.
22. van Vugt JL, Levoller S, Gharbharan A, Koek M, Niessen WJ, Burger JW, *et al.* A comparative study of software programmes for cross-sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patients. *J Cachexia Sarcopenia Muscle* 2017;8:285–97.
23. TomoVision. 2023 [Internet]. Available from: <http://www.tomovision.com> [cited 2023, Oct 26].
24. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, *et al.* Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. *Lancet Oncol* 2008;9:629–35.
25. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. *J Appl Physiol* 1998;85:115–22.
26. Lieffers JR, Bathe OF, Fassbender K, Winget M, Baracos VE. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. *Br J Cancer* 2012;107:931–6.
27. Bahat G, Turkmen BO, Aliyev S, Catikkas NM, Bakir B, Karan MA. Cut-off values of skeletal muscle index and psoas muscle index at L3 vertebra level by computerized tomography to assess low muscle mass. *Clin Nutr* 2021;40:4360–5.
28. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;240:205–13.
29. Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, *et al.*; American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology, Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention. Exercise standards for testing and training: a scientific statement from the American Heart Association. *Circulation* 2013;128:873–934.
30. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of Adl: a standardized measure of biological and psychosocial function. *JAMA* 1963;185:914–9.
31. Bradley NA, Walter A, Dolan R, Wilson A, Siddiqui T, Roxburgh CS, *et al.* Evaluation of the prognostic value of computed tomography-derived body composition in patients undergoing endovascular aneurysm repair. *J Cachexia Sarcopenia Muscle* 2023;14:1836–47.
32. Moll FL, Powell JT, Fraedrich G, Verzini F, Haulon S, Waltham M, *et al.*; European Society for Vascular Surgery. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. *Eur J Vasc Endovasc Surg* 2011;41(Suppl 1):S1–58.
33. Chaikof EL, Dalman RL, Eskandari MK, Jackson BM, Lee WA, Mansour MA, *et al.* The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. *J Vasc Surg* 2018;67:2–77.e2.
34. Hughes MJ, Hackney RJ, Lamb PJ, Wigmore SJ, Christopher Deans DA, Skipworth RJ. Prehabilitation Before Major Abdominal Surgery: A Systematic Review and Meta-analysis. *World J Surg* 2019;43:1661–8.
35. Moran J, Guinan E, McCormick P, Larkin J, Mockler D, Hussey J, *et al.* The ability of prehabilitation to influence postoperative outcome after intra-abdominal operation: A systematic review and meta-analysis. *Surgery* 2016;160:1189–201.
36. Fenton C, Tan AR, Abaraogu UO, McCaslin JE. Prehabilitation exercise therapy before elective abdominal aortic aneurysm repair. *Cochrane Database Syst Rev* 2021;7:CD013662.
37. Lichtenberg T, von Stengel S, Sieber C, Kemmler W. The Favorable Effects of a High-Intensity Resistance Training on Sarcopenia in Older Community-Dwelling Men with Osteosarcopenia: The Randomized Controlled FrOST Study. *Clin Interv Aging* 2019;14:2173–86.
38. Martín Del Campo Cervantes J, Habacuc Macías Cervantes M, Monroy Torres R. Effect of a Resistance Training Program on Sarcopenia and Functionality of the Older Adults Living in a Nursing Home. *J Nutr Health Aging* 2019;23:829–36.

Conflicts of interest

The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

Authors' contributions

Jan van Schaik and Joost R. van der Vorst contributed equally and share senior authorship. All authors contributed to the study conception. Study design was drafted by Britt W. Warmerdam, Joost R. van der Vorst, and Jan van Schaik. Material preparation, data collection and analysis were performed by Britt W. Warmerdam, Carla S. van Rijswijk, Anneke Droop, and Claudia J. Lucassen. The first draft of the manuscript was written by Britt W. Warmerdam, Joost R. van der Vorst, and Jan van Schaik, which was edited by Jaap F. Hamming. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

History

Article first published online: November 21, 2023. - Manuscript accepted: October 25, 2023. - Manuscript revised: October 16, 2023. - Manuscript received: July 27, 2023.

SUPPLEMENTARY DIGITAL MATERIAL 1

Supplementary Table I.—Comparison of patient characteristics.

Variable	Sarcopenic PMI (N.=24)	Not sarcopenic PMI (N.=77)	P value	Sarcopenic SMI (N.=64)	Not sarcopenic SMI (N.=30)	P value	Sarcopenic LPMA (N.=53)	Not sarcopenic LPMA (N.=48)	P value
Male gender	22 (92)	62 (81)	0.348	55 (86)	22 (73)	0.158	36 (68)	48 (100)	<0.001
Age	75.3 (6.0)	73.4 (6.1)	0.199	74.83 (6.5)	72.6 (5.1)	0.076	74.3 (6.2)	73.3 (6.1)	0.394
BMI	25.4 (4.4)	26.7 (3.3)	0.115	25.5 (3.5)	28.3 (3.6)	<0.001	26.2 (4.2)	26.7 (3.0)	0.518
ASA-score									
- 2	7 (29)	31 (40)	0.219	26 (41)	9 (30)	0.507	18 (34)	20 (42)	0.822
- 3	15 (63)	44 (57)		36 (56)	19 (63)		33 (62)	26 (54)	
- 4	2 (8)	2 (3)		2 (3)	2 (7)		2 (4)	2 (4)	
Aneurysm size	62.0 (59.0-74.3)	65.0 (58.5-70.0)	0.867	64.5 (60.0-69.0)	66.0 (58.0-76.0)	0.403	64.0 (60.0-69.5)	65.5 (58.0-74.8)	
Procedure complexity*									
- Grade 1	5 (21)	9 (12)	0.709	9 (14)	4 (13)	0.597	4 (8)	10 (21)	0.169
- Grade 2	10 (42)	34 (44)		32 (50)	11 (37)		22 (42)	22 (46)	
- Grade 3	7 (29)	27 (35)		18 (28)	12 (40)		21 (39)	13 (27)	
- Grade 4	2 (8)	7 (9)		5 (8)	3 (10)		6 (11)	3 (6)	
MI/ACS	9 (38)	26 (34)	0.808	21 (33)	12 (40)	0.643	15 (28)	20 (42)	0.209
AF	4 (17)	11 (14)	0.750	7 (11)	6 (20)	0.336	8 (15)	7 (15)	1.000
Other cardiovascular disease	11 (46)	21 (27)	0.130	21 (33)	8 (27)	0.636	22 (42)	10 (21)	0.033
COPD	6 (25)	17 (22)	0.784	19 (30)	4 (13)	0.122	14 (26)	9 (19)	0.477
Diabetes type 2	3 (13)	11(14)	1.000	6 (9)	7 (23)	0.106	6 (11)	8 (17)	0.567
Previous AAA repair**	9 (38)	10 (13)	0.014	11 (17)	4 (13)	0.768	11 (21)	9 (19)	0.622
PVD	4 (17)	13 (17)	1.000	10 (16)	7 (23)	0.397	9 (17)	8 (17)	1.000
Stroke	3 (13)	20 (26)	0.265	14 (22)	8 (27)	0.794	8 (15)	15 (31)	0.061
Malignancy									
- Active	1 (4)	4 (5)	0.501	2 (3)	3 (10)	0.419	3 (6)	2 (4)	0.593
- Past	8 (33)	17 (22)		16 (25)	6 (20)		11 (21)	14 (29)	
Smoking				(N.=63)			(N.=52)		
- Active	7 (29)	22 (29)	0.706	15 (24)	10 (33)	0.264	12 (23)	17 (35)	0.382
- Past	11 (46)	41(53)		33 (52)	17 (57)		30 (58)	22 (46)	
Hypertension	15 (63)	61 (79)	0.111	48 (75)	23 (77)	1.000	42 (79)	34 (71)	0.363
Hypercholesterolemia	6 (25)	29 (38)	0.329	23 (36)	10 (33)	0.822	17 (32)	18 (38)	0.676
MET-score	(N.=20)	(N.=69)		(N.=56)	(N.=26)		(N.=44)	(N.=45)	

- Low (1-4) - Average (4-7) - High (7-10)	5 (25) 14 (70) 1 (5)	11 (16) 56 (81) 2 (3)	0.349	11 (20) 42 (75) 3 (5)	4 (15) 22 (8) 0	0.638	10 32 2	6 (13) 38 (84) 1 (2)	0.408
PMI	4.8 (4.2-5.2)	6.3 (5.8-7.3)	<0.001	5.6 (1.2)	7.2 (1.5)	<0.001	5.2 (4.7-6.1)	6.9 (6.1-7.8)	<0.001
SMI	40.6 (5.411)	48.0 (7.5)	<0.001	44.3 (38.6-48.1)	55.5 (52.5-57.9)	<0.001	42.4 (6.6)	51.0 (6.3)	<0.001
LPMA	226.5 (160.9-331.2)	379.5 (305.4-478.2)	<0.001	328.0 (110.3)	451.0 (177.1)	0.001	289.3 (229.8-318.0)	457.3 (385.5- 531.4)	<0.001

BMI: Body Mass Index (kg/m²); ASA: American Association of Anesthesiologists; MI/ACS: myocardial infarction/acute coronary syndrome; AF: atrial fibrillation; COPD: chronic obstructive pulmonary disease; AAA: aortic aneurysm repair; PVD: peripheral vascular disease; MET: Metabolic Equivalent of Task; PMI: Psoas Muscle Index; SMI: Skeletal Muscle Index.

*Grade 1: 1 or 2 fenestrations. Grade 2: 3 or 4 fenestrated EVAR. Grade 3: branched-EVAR. Grade 4: branched-fenestrated EVAR combinations, arch EVAR, and emergency cases; **either open or endovascular.